Your browser doesn't support javascript.
loading
The Leprosy Post-Exposure Prophylaxis (LPEP) programme: update and interim analysis.
Steinmann, Peter; Cavaliero, Arielle; Aerts, Ann; Anand, Sunil; Arif, Mohammad; Ay, Sarady Sao; Aye, Tin Maung; Barth-Jaeggi, Tanja; Banstola, Nand Lal; Bhandari, Chuda Mani; Blaney, David; Bonenberger, Marc; VAN Brakel, Wim; Cross, Hugh; DAS, V K; Fahrudda, Ansarul; Fernando, Nilanthi; Gani, Zaahira; Greter, Helena; Ignotti, Eliane; Kamara, Deus; Kasang, Christa; Kömm, Burkard; Kumar, Anil; Lay, Sambath; Mieras, Liesbeth; Mirza, Fareed; Mutayoba, Beatrice; Njako, Blasdus; Pakasi, Tiara; Saunderson, Paul; Shengelia, Bakhuti; Smith, Cairns S; Stäheli, René; Suriyarachchi, Nayani; Shwe, Tin; Tiwari, Anuj; Wijesinghe, Millawage Supun D; VAN Berkel, Jan; Vander Plaetse, Bart; Virmond, Marcos; Richardus, Jan Hendrik.
Afiliação
  • Steinmann P; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Cavaliero A; University of Basel, Basel, Switzerland.
  • Aerts A; Novartis Foundation, Basel, Switzerland.
  • Anand S; Novartis Foundation, Basel, Switzerland.
  • Arif M; American Leprosy Missions, Hyderabad, India.
  • Ay SS; Netherlands Leprosy Relief, New Delhi, India.
  • Aye TM; Swiss Tropical and Public Health Institute, Phnom Penh, Cambodia.
  • Barth-Jaeggi T; American Leprosy Missions, Yangon, Myanmar.
  • Banstola NL; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Bhandari CM; University of Basel, Basel, Switzerland.
  • Blaney D; Netherlands Leprosy Relief, Kathmandu, Nepal.
  • Bonenberger M; Department of Health Services, Kathmandu, Nepal.
  • VAN Brakel W; Centers for Disease Control and Prevention, Atlanta, USA.
  • Cross H; FAIRMED, Bern, Switzerland.
  • DAS VK; Netherlands Leprosy Relief, Amsterdam, The Netherlands.
  • Fahrudda A; Private, United Kingdom.
  • Fernando N; Health Services, Dadra and Nagar Haveli, India.
  • Gani Z; East Java Provincial Health Office, Surabaya, Indonesia.
  • Greter H; Anti-Leprosy Campaign, Colombo, Sri Lanka.
  • Ignotti E; Novartis Foundation, Basel, Switzerland.
  • Kamara D; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Kasang C; University of Basel, Basel, Switzerland.
  • Kömm B; Universidade do Estado de Mato Grosso, Cáceres, Brasil.
  • Kumar A; National Tuberculosis and Leprosy Programmeme, Dar es Salaam, Tanzania.
  • Lay S; German Leprosy and Tuberculosis Relief Association, Würzburg, Germany.
  • Mieras L; German Leprosy and Tuberculosis Relief Association, Würzburg, Germany.
  • Mirza F; Directorate General of Health Services, MoHFW, New Delhi, India.
  • Mutayoba B; National Leprosy Elimination Programme, Phnom Penh, Cambodia.
  • Njako B; Netherlands Leprosy Relief, Amsterdam, The Netherlands.
  • Pakasi T; Novartis Foundation, Basel, Switzerland.
  • Saunderson P; National Tuberculosis and Leprosy Programmeme, Dar es Salaam, Tanzania.
  • Shengelia B; German Leprosy and Tuberculosis Relief Association, Dar es Salaam, Tanzania.
  • Smith CS; Sub Directorate Directly Transmitted Tropical Diseases, MoH, Jakarta, Indonesia.
  • Stäheli R; American Leprosy Missions, Greenville, USA.
  • Suriyarachchi N; Novartis Foundation, Basel, Switzerland.
  • Shwe T; University of Aberdeen, Aberdeen, United Kingdom.
  • Tiwari A; FAIRMED, Bern, Switzerland.
  • Wijesinghe MSD; FAIRMED, Colombo, Sri Lanka.
  • VAN Berkel J; American Leprosy Missions, Yangon, Myanmar.
  • Vander Plaetse B; Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Virmond M; Anti-Leprosy Campaign, Colombo, Sri Lanka.
  • Richardus JH; Netherlands Leprosy Relief, Amsterdam, The Netherlands.
Lepr Rev ; 89(2): 102-116, 2018.
Article em En | MEDLINE | ID: mdl-37180343
ABSTRACT
Innovative approaches are required to further enhance leprosy control, reduce the number of people developing leprosy, and curb transmission. Early case detection, contact screening, and chemoprophylaxis currently is the most promising approach to achieve this goal. The Leprosy Post-Exposure Prophylaxis (LPEP) programme generates evidence on the feasibility of integrating contact tracing and single-dose rifampicin (SDR) administration into routine leprosy control activities in different settings. The LPEP programme is implemented within the leprosy control programmes of Brazil, Cambodia, India, Indonesia, Myanmar, Nepal, Sri Lanka and Tanzania. Focus is on three key

interventions:

tracing the contacts of newly diagnosed leprosy patients; screening the contacts for leprosy; and administering SDR to eligible contacts. Country-specific protocol adaptations refer to contact definition, minimal age for SDR, and staff involved. Central coordination, detailed documentation and rigorous supervision ensure quality evidence. Around 2 years of field work had been completed in seven countries by July 2017. The 5,941 enrolled index patients (89·4% of the registered) identified a total of 123,311 contacts, of which 99·1% were traced and screened. Among them, 406 new leprosy patients were identified (329/100,000), and 10,883 (8·9%) were excluded from SDR for various reasons. Also, 785 contacts (0·7%) refused the prophylactic treatment with SDR. Overall, SDR was administered to 89·0% of the listed contacts. Post-exposure prophylaxis with SDR is safe; can be integrated into the routines of different leprosy control programmes; and is generally well accepted by index patients, their contacts and the health workforce. The programme has also invigorated local leprosy control.

Texto completo: 1 Tema: Epidemiologia / Geral / Prevencao_controle / Transmissao Bases de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline Idioma: En Revista: Lepr Rev Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Tema: Epidemiologia / Geral / Prevencao_controle / Transmissao Bases de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline Idioma: En Revista: Lepr Rev Ano de publicação: 2018 Tipo de documento: Article